Dasatinib

Drug Profile

Dasatinib

Alternative Names: BMS-354825; Sprycel

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
  • Phase I/II Glioblastoma; Non-Hodgkin's lymphoma
  • No development reported Colorectal cancer; Leukaemia; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer
  • Discontinued Pancreatic cancer; Scleroderma

Most Recent Events

  • 10 Nov 2017 Registered for Chronic myeloid leukaemia (In adolescents, In children) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Combination therapy) in Australia (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Combination therapy) in Canada (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top